A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT)

PURPOSE: Regorafenib monotherapy, a multikinase inhibitor of angiogenesis, tumor microenvironment, and tumorigenesis, showed promising results in gastric cancer. We aimed to assess the tolerability of regorafenib and paclitaxel in patients with advanced esophagogastric cancer (EGC) refractory to fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Stroes, Charlotte I, Schokker, Sandor, Khurshed, Mohammed, van der Woude, Stephanie O, Mathôt, Ron AA, Slingerland, Marije, de Vos-Geelen, Judith, Zucchetti, Massimo, Matteo, Cristina, van Dijk, Erik, Ylstra, Bauke, Thijssen, Victor, Derks, Sarah, Godefa, Tesfay, Dijksterhuis, Willemieke, Breimer, Gerben E, van Delden, Otto M, Verhoeven, Rob HA, Meijer, Sybren L, Bijlsma, Maarten F, van Laarhoven, Hanneke WM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244942/
https://www.ncbi.nlm.nih.gov/pubmed/35782751
http://dx.doi.org/10.1177/17588359221109196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244942/
https://www.ncbi.nlm.nih.gov/pubmed/35782751
http://dx.doi.org/10.1177/17588359221109196

Ejemplares similares